title: [A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases].
abstract: A case of gastric endocrine cell carcinoma successfully treated by FU (5-FU/UFT) +irinotecan (CPT-11) adjuvant therapy against recurrent metastases is reported with some discussion. A 69-year-old man was admitted to our hospital with severe anemia. He was diagnosed with advanced gastric cancer, T3N1H0P0M0, Stage IIIa. Total gastrectomy with pancreato-splenectomy with D2 lymph node dissection was done for curative resection. The pathological diagnosis was gastric endocrine cell carcinoma because Grimelius and Chromogranin A stained positive histologically. Seven months after operation, recurrent liver metastases with tumor embolism of the portal vein were revealed by enhanced CT examination. FU (5-FU/UFT) +CPT-11 was done as the first-line adjuvant chemotherapy. Metastatic lesion of the liver and portal vein tumor embolism was decreased. Tumor marker CA19-9 level was also decreased and within normal limits. This therapy was evaluated as a partial response (PR) in twelve months and the patient died three years and eight months after operation. Gastric endocrine cell carcinoma is known as a potentially highly malignant tumor. But in our case FU+CPT-11 controlled growth of the recurrent tumor. Based on this finding, we recommend adjuvant chemotherapy by FU+CPT-11 for gastric endocrine cell carcinoma.
authors.affiliation: Dept. of Surgery, Kiryu Kosei General Hospital.
authors.forename: Tomonori
authors.initials: T
authors.lastname: Tsuchiya
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Hiramatsu
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tanaka
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Machiki
authors.forename: Tadayuki
authors.initials: T
authors.lastname: Sakuragawa
authors.forename: Hidehiko
authors.initials: H
authors.lastname: Otsuji
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Hara
authors.forename: Akiharu
authors.initials: A
authors.lastname: Kimura
authors.forename: Katsue
authors.initials: K
authors.lastname: Yoshida
authors.forename: Jun
authors.initials: J
authors.lastname: Hosoya
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Kojima
authors.forename: Kenji
authors.initials: K
authors.lastname: Kato
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D017024:Chemotherapy, Adjuvant; D005472:Fluorouracil / Q000008:administration & dosage; D005743:Gastrectomy; D006801:Humans; D000077146:Irinotecan; D008197:Lymph Node Excision; D008297:Male; D009362:Neoplasm Metastasis; D013274:Stomach Neoplasms / Q000628:therapy*; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D005641:Tegafur; D014498:Uracil; D000077146:Irinotecan; D005472:Fluorouracil; D002166:Camptothecin